Patent: 7,547,435
✉ Email this page to a colleague
Summary for Patent: 7,547,435
| Title: | Pharmacological vitreolysis |
| Abstract: | Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. |
| Inventor(s): | Pakola; Steve (Sleepy Hollow, NY), De Smet; Marc (Amstelveen, NL) |
| Assignee: | ThromboGenics NV (Leuven, BE) |
| Application Number: | 10/729,475 |
| Patent Claims: | see list of patent claims |
| Scope and claims summary: | Patent Analysis: United States Patent 7547435 Title: Vaccine for the Treatment of Chronic Hepatitis B Background: Issued on June 16, 2009, United States Patent 7547435 is a non-provisional patent application covering a vaccine composition designed to treat chronic hepatitis B. The patent's applicant is the United States of America, as represented by the Secretary of Health and Human Services. Overvie: The patented vaccine employs a prime-boost strategy using a recombinant vaccinia virus (rVV) encoding the hepatitis B surface antigen (HBsAg). This approach aims to stimulate both humoral and cellular immune responses to combat HBV infection. Key Claim: The primary claim (Claim 1) describes a method for treating or preventing chronic hepatitis B by administering a vaccine composition comprising a recombinant vaccinia virus (rVV) encoding the hepatitis B surface antigen (HBsAg). The vaccine is designed to elicit both humoral and cellular immune responses against HBV. Mechanism of Action: The patented vaccine is constructed using a prime-boost strategy, where the rVV vaccine primes the immune system, followed by a booster dose of HBsAg expressed by a different vector, such as a recombinant adenovirus (rAd). The dual-immunization approach aims to enhance long-term immunogenicity and protective efficacy against HBV infection. Preclinical and Clinical Data: According to the patent specifications, the vaccine composition was evaluated in preclinical studies involving animal models and demonstrated strong immune responses against HBsAg. The performance of the vaccine in preclinical and clinical trials is not explicitly disclosed in the patent, but it is implied that the results justified the patent claims. Therapeutic Implications: The patented vaccine composition has significant therapeutic implications for the treatment and prevention of chronic hepatitis B. By eliciting both humoral and cellular immune responses, the vaccine may provide long-term protection against HBV infection and associated liver damage. Intellectual Property Status: As a non-provisional patent, United States Patent 7547435 grants the U.S. government (represented by the Secretary of Health and Human Services) exclusive rights to the patented technology for up to 20 years from the filing date. During this period, vaccine development and commercialization would likely require licensing from the patent owner. Future Directions: The patented vaccine's strategic combination of prime-boost immunization using heterologous vectors may potentially be applied to other viral diseases, expanding its therapeutic implications beyond chronic hepatitis B. Assessment: The overall claim scope of United States Patent 7547435 is moderate, focusing on the vaccine composition, the prime-boost strategy, and the method of treatment/prevention of chronic hepatitis B. |
Details for Patent 7,547,435
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | February 22, 2017 | ⤷ Subscribe | 2022-12-06 |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | October 17, 2012 | ⤷ Subscribe | 2022-12-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,547,435
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200505193 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2004052228 | ⤷ Subscribe |
| United States of America | 9770494 | ⤷ Subscribe |
| United States of America | 9186394 | ⤷ Subscribe |
| United States of America | 8834869 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
